Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360134 | 0.92 | HPGD (0.47) | HPGDALDH1A1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL6013194 | 0.88 | HPGD (0.44) | HPGDALDH1A1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL9259815 | 0.86 | HPGD (0.43) | HPGDALDH1A1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL9614726 | 0.82 | HPGD (0.40) | HPGDALDH1A1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL620188 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL5306922 | 0.74 | KDM4E (0.32) | HPGDALDH1A1ALOX15MAPTTSHR | |
| SCHEMBL709354 | 0.73 | LMNA (0.39) | HPGDALDH1A1RAB9ASMN1; SMN2LMNA | |
| Malonic Acid SCHEMBL11132579 | 0.73 | LDHA (0.36) | — | |
| SCHEMBL9564059 | 0.73 | HPGD (0.45) | HPGDALDH1A1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL711756 | 0.73 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| EP-1989179-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-26 | — | — | EP | disclosed |
| US-20100111875-A1 | TRISUBSTITUTED TRIAZAMACROCYCLIC COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
| US-20100111875-A1 | TRISUBSTITUTED TRIAZAMACROCYCLIC COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
| US-20100111875-A1 | TRISUBSTITUTED TRIAZAMACROCYCLIC COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
| EP-2129664-A1 | TRISUBSTITUTED TRIAZAMACROCYCLI C COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE Healthcare AS (NO) | 2009-12-09 | — | — | EP | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| EP-1989179-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2008-11-12 | — | — | EP | disclosed |
| US-20080260651-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-23 | — | — | US | disclosed |
| US-20080260651-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-23 | — | — | US | disclosed |
| US-20080260651-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-23 | — | — | US | disclosed |
| WO-2008123779-A1 | TRISUBSTITUTED TRIAZAMACROCYCLI C COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123779-A1 | TRISUBSTITUTED TRIAZAMACROCYCLI C COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007094683-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | HPGD 3025/4885ALDH1A1 3352/4885RAB9A 1905/4885 |
| US-20080260651-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | HPGD 1100/4885ALDH1A1 3375/4885RAB9A 1046/4885 |
| US-20100111875-A1 | TRISUBSTITUTED TRIAZAMACROCYCLIC COMPOUNDS AND THEIR USE AS CONTRAST AGENTS | TBCA, THOC2, TCOF1 | HPGD 1841/4885ALDH1A1 3570/4885RAB9A 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.